Supreme Court Temporarily Restores Mifepristone Access by Mail

Today, the Supreme Court temporarily restored nationwide access to the abortion pill mifepristone by mail, pausing a lower-court ruling that had blocked providers from prescribing it via telemedicine, according to reporting by The New York Times.¹

Justice Samuel A. Alito Jr issued a one-sentence administrative stay of Friday’s decision, halting its implementation until at least May 11. Briefs from both parties are due Thursday, after which the full court will determine how to proceed.

Mifepristone is considered a safe and effective way to end early pregnancies and is typically used in combination with a second drug, misoprostol.² The drug was approved by the FDA in 2000, with a first generic version authorized in 2019 and a second approved last October.

The most recent approval drew criticism from antiabortion leaders. Former Vice President Mike Pence called it “a complete betrayal of the pro-life movement that elected President Trump” and urged HHS Secretary Robert F. Kennedy Jr to resign. Sen Josh Hawley (R, Missouri) also said he had “lost confidence in the leadership at FDA.”

5th Circuit Ruling Restricts Mail Access

Friday’s decision stemmed from a lawsuit filed by Louisiana against the FDA, seeking to limit access to mifepristone by mail. The state argued that mail distribution undermines its near-total ban enacted after the Supreme Court overturned the Roe v Wade ruling in 2022.^1,3

A unanimous 3-judge panel of the New Orleans-based Fifth US Circuit Court of Appeals sided with Louisiana, ruling that the drug must be dispensed in person at clinics.⁴ Pro-choice group Reproductive Freedom for All condemned the decision, claiming it moves the US closer to a national abortion ban.⁵

“Anti-abortion politicians know their policies are unpopular, so they are using every lever of government they can,” Reproductive Freedom for All President and CEO Mini Timmaraju said in a news release. “Louisiana built this case on debunked, junk science. The safety of mifepristone has never actually been in question. As this case moves towards the US Supreme Court, we will fight until every person has access to the care they need.”

Mifepristone manufacturers Danco Laboratories and GenBioPro also asked the Supreme Court to intervene, warning the decision would disrupt care nationwide.¹ Alito, who handles emergency applications from the Fifth Circuit, acted independently to issue the temporary pause. However, his order does not indicate how the full court may handle the case.

Without the intervention, the decision would have reversed FDA regulations issued in 2021 that allowed mifepristone to be prescribed via telehealth and delivered by mail during the COVID-19 pandemic, based on evidence that patients could safely use the medication without direct supervision.⁴

Since Roe v Wade was overturned, Republican-led states have enacted strict abortion bans, while many Democratic-led states have passed shield laws protecting clinicians who prescribe abortion pills via telemedicine across state lines.¹ Opponents of mail distribution, like Louisiana, argue it introduces safety risks and increases health care costs in states where abortion is restricted.

Data Underscore Growing Reliance on Telehealth for Abortion Access

Even as legal challenges continue, surveys show that most abortions in the US are provided via pills, with about 1 in 4 abortions prescribed via telehealth. One recent study found that requests for telehealth medication abortion services nearly doubled across 18 states after the Supreme Court overturned Roe v Wade in 2022, particularly among individuals living further from in-person abortion care.⁶

“The loss of federal abortion protections has significantly disrupted access even in states with robust service provision,” the authors concluded. “Our results highlight the critical role of [telehealth medication abortion] in reducing geographic barriers to care and underscore the need to expand teleMAB access nationwide.”

References

1. Marimow AE. Supreme Court temporarily restores access to abortion pill by mail. The New York Times. May 4, 2026. Accessed May 4, 2026.
2. Mattina C. FDA approves second generic mifepristone pill for abortion. AJMC^®. October 3, 2025. Accessed May 4, 2026. https://www.ajmc.com/view/fda-approves-second-generic-mifepristone-pill-for-abortion
3. Inserro A. Supreme Court overturns Roe v Wade, turning issue back to states. AJMC. June 24, 2022. Accessed May 4, 2026. https://www.ajmc.com/view/supreme-court-overturns-roe-v-wade-turning-issue-back-to-states
4. Mulvihill G, Schoenbaum H. Court restricts abortion access across the US by blocking the mailing of mifepristone. Associated Press. May 1, 2026. Accessed May 4, 2026. https://apnews.com/article/abortion-pills-mail-louisiana-ruling-40d60a9bf6212480e527480757b603c3
5. Reproductive Freedom for All condemns Fifth Circuit decision gutting telehealth access to mifepristone nationwide. News release. Reproductive Freedom for All. May 1, 2026. Accessed May 4, 2026. https://reproductivefreedomforall.org/news/reproductive-freedom-for-all-condemns-fifth-circuit-decision-gutting-telehealth-access-to-mifepristone-nationwide/
6. McCrear S. Telehealth requests for medication abortion double post Dobbs ruling. AJMC. October 21, 2025. Accessed May 4, 2026. https://www.ajmc.com/view/telehealth-requests-for-medication-abortion-double-post-dobbs-ruling